碳铂的临床药代动力学
作者：蒋学华,廖工铁
Author：
收稿日期： 年卷（期）页码：1993,(01):-42-46
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：碳铂的临床药代动力学
Key words：
基金项目：
中文摘要
碳铂(卡铂、Carboplatin、Paraplatin、CBDCA、JM8)是铂类抗癌药的第二代产品,由Cleare等于1980年发现其抗癌活性,英国于1986年3月率先上市,国内于
参考文献
1． Cleare MJ, et al. in Prestagko AW et al (eds). Cisplatin: Current Status and New Developments. New York, Acadcmic Press 1980: P149～166．
2． Calvert AH, et al. Cancer Chemother Pharmacol, 1982; 9: 140．
3． Rogencweig M, et al. J Clin Oncol 1983; 1: 621．
4． Van Echo DA, et al. Cancer Treat Rep 1984; 68: 1103．
5． Canetta, et al. Cancer Treat Rev 1988; 15:17．
6． Knox RJ. et al. Cancer Res 1986; 46: 1972．
7． Gaynon et al. Cancer Treat Rep 1987; 71: 1034．
8． 何友兼,等.癌症 1990;9(6) :449．
9． Van Hennik MB, et al. Cancer Chemother Pharmacol 1989; 23:126．
10． Elferink F, et al. Cancer Chemother Pharmacol 1988; 21:57．
11． Goel R, et al. Journal of the National Cancer Institute 1989; 81: 1552．
12． Elferink F, et al. Cancer Treat Rep 1987; 71: 1231．
13． 彭彬,等。癌症 1990;9(6) :452．
14． Newell DR, et al. European Journal of Cancer and Chnical Oncology 1987; 23: 1399．
15． Hecquet B, et al. Bulletin du Cancer 1987; 74: 433．
16． Owens SE, et al. Cancer Chemother Pharmacol 1985; 14: 253．
17． SiddiK ZH, et al. in Hacker et al(Eds). Platinum Coordiination compexes in Cancer Chemotherapy P90, Martinus Nijhoff Publishing, Boston, 1984．
18． Sidcik ZH, et al. in Mc Brien & Slater (Eds). Biomedical Mechanisms of Platinum Antitumor Drugs, P171; IRL Press Limited Oxford, 1986．
19． Shea TC, et al. Journal of Chinical Oncology 1989; 7: 651．
20． Vlasveld LT, et al. Cancer Chemother Pharmacol 1990; 25: 382．
21． Dible SE, et al. Cancer Chemother Pharmacol 1988; 22: 11．
22． Oguri S, et al. Journal of Clinical Pharmacology 1988; 28: 208．
23． 彭彬,等.中国临床药理学杂志 1987;3(1) :1．
24． Gaver RC, et al. Cancer Chemother Pharmacol 1987; 20: 271．
25． Ew en C, et al. Cancer Chemother Pharmaco 1988; 22: 241．
26． Tjioe PS, et al. Journal of Radioanalytical and Nuclear Chemistry 1986; 104: 103．
27． Bannister SJ, et al. J. Chromatogr 1983; 273: 301．
28． Elferink F, et al. Analytical Chemistry 1986; 58: 2293．
29． Tycgkowska K. et al. Europan Journal of Cancer and Clnical Oncology 1988; 24: 621．
30． Andrews PA, et al. Analytical Biochem 1984; 153:46．
31． Gaver RC, et al, Cancer Chemother Pharmacol. 1986; 19:201．
32． Egorin MJ, et al. Cancer Res 1984; 44: 4532．
33． Egorin MJ, et al. Cancer, Res 1987; 47: 3606．
34． Van Echo, et al. Seminars in Oncology 1989; 16: 1．
36． Belani CP, et al. Journal of Clinical Oncology 1989; 7: 1896．
36． Egorin MJ, et al. Cancer Res 1985; 45: 6502．
37． Fish RG, et al. Cancer. Res 1987; 47:3606．
38． Ogols RF, et al. Seminars in Oncology 1989; 16: 14．
39． Calvert AH, et al. Journal of Clinical Oncology 1989; 7: 1748．
40． Van Echo DA, et al. Cancer Treat Rep 1984; 68: 1103．
41． Lee EJ, et al. Journal of the National Cancer Institute 1988; 80: 131．
42． El-yaziga A, et al. Pharmaceutical Research 1989; 6:492．
43． Mulder POM, et all. British Journal of Cancer 1990; 61:460．
44． 张玫,等。中华肿癌杂志 1991;13(2) :120．
45． Curt GA, et al. Cancer Res 1983; 43:4470．
46． Harland SJ, et al. Cancer Res 1984;44: 1693．
47． Koeller JM, et al. Cancer 1986; 57:222．
48． Gaver RC, et al. Cancer Chemother Pharmacol 1988; 22: 263．
49． Tosetti F, et al,Anticancer Research 1988; 8: 381．
50． Sasaki Y, et al. Cancer Chemother Pharmacol 1989; 23: 243．
51． Reece PA, et al. Cancer Chemother Pharmacol 1987; 19: 326．
52． Trump DL, et al. Journal of Clinical Oncology 1987; 5: 1281．
【关闭】
